 |
|
 |
 |
|
||||||
College House
|
Welcome to the Women's Health pageWomen's healthThe College works to provide the highest quality specialist care to women and is dedicated to pursuing excellence in the delivery of health care to women throughout their lives. The College produces Patient Information Pamphlets on 23 topics from exercise during pregnancy to antenatal care and routine tests during pregnancy to caesarean section. For your information, we have assembled a list of websites which compile well researched information on women's health More Termination of PregnancyA resource for health professionalsThis RANZCOG publication was approved by the College Council at the November 2005 meeting.Its preparation has been overseen by the Women’s Health Committee of the RANZCOG with the assistance of a working party comprising Fellows of RANZCOG and external contributors More Important Notice Regarding the Availability of Ergometrine MaleateIn Australia Ergometrine Maleate .5mgs/ml, will not be available for several months once current stocks are exhausted. This does not affect New Zealand , we understand that New Zealand stocks are adequate. Supplies of Syntometrine 1 ml ampoule (.5mgs Ergometrine Maleate + 5 I.U. Oxytocin) will not be affected. Syntometrine can be substituted for Ergometrine when necessary. 1 ml of Syntometrine (containing .5mgs of Ergometrine Maleate and 5 I.U. of Oxytocin) can be used as a substitute for 1 ml of Ergometrine (containing .5mgs of Ergometrine) or 0.5 ml Syntometrine (containing 0.25mg Ergometrine and 2.5ml of Syntocinon) can be used as a substitute for 0.5 ml of Ergometrine. These links lead to consumer medicine information sheets that describe the substances and how they are prepared and packaged: http://www.maynepharma.com/AU/Files/Ergometrine_cmi.pdf Ergometrine consumer medicine information sheet http://www.betterhealth.vic.gov.au/bhcv2/bhcmed.nsf/pages/nvcmetin/$File/nvcmetin.pdf Syntometrine consumer medicine information sheet Revised & Updated College StatementsCollege Statements updateA number of College Statements are reviewed by the Women's Health Committee three times each year More TGA Advice on Paroxetine and PregnancyCaution over antidepressant paroxetine during pregnancyThe Therapeutic Goods Administration (TGA) issued the following information on 7 September 2005: "Australia's medicines watchdog, the Therapeutic Goods Administration (TGA), has today advised pregnant women who are taking the antidepressant, Paroxetine, to discuss this treatment with their doctor, following some new information from overseas that suggests there may be a slight increased risk to their babies. "Preliminary analysis of data from a large study conducted in the United States suggests that there may be an increased risk of birth defects and cardiovascular malformation in babies whose mothers are taking Paroxetine. "Australia's Chief Medical Officer, Professor John Horvath, has cautioned pregnant women not to suddenly discontinue using the medicine as the withdrawal symptoms could be harmful." Read the rest of the TGA media release The TGA also issued three fact sheets on SSRIs and paroxetine:
GlaxoSmithKline information lineThe manufacturer of paroxetine, GlaxoSmithKline, has set up an information line for women and health professionals: (t) 1800 010 462 Women's Health MattersIodine Supplementation in PregnancyMore
( Advice to medical practitioners about the use of postmenopausal hormone therapyMore
( Elective caesarean sections at maternal requestMore
( Elective caesarean section: a patient's accountMore
( Hysterectomy vs non-surgical therapies: Should gynaecologists consider alternative techniques for heavy periods?More
( Homebirths in Australia: Viewpoints from a patient, a midwife and an obstetricianMore
( Homebirths in New Zealand: Perspectives of an obstetrician and midwifeMore
(
© RANZCOG
|
|
91 KB)
(O&G, Vol 7, No 1) 
